The impact of COVID‐19 on multi‐month dispensing (MMD) policies for antiretroviral therapy (ART) and MMD uptake in 21 PEPFAR‐supported countries: a multi‐country analysis. (28th October 2021)

• Record Type: Journal Article
• Authors: Bailey, Lauren E.; Siberry, George K.; Agaba, Patricia; Douglas, Meaghan; Clinkscales, Jessica R.; Godfrey, Catherine
• Is Part Of: Journal of the International AIDS Society. Volume 24(2021)Supplement 6
• Page Start: n/a
• Page End: n/a
• Publication Date: 2021-10-28
• Subjects: ART -- COVID‐19 -- MMD -- PEPFAR -- treatment continuity -- viral load; AIDS (Disease) -- Periodicals; HIV infections -- Periodicals; 616.9792005
• DOI: 10.1002/jia2.25794
• Languages: English
• ISSNs: 1758-2652

Abstract

Abstract: Introduction: Increasing access to multi‐month dispensing (MMD) of antiretroviral therapy (ART) supports treatment continuity and viral load suppression for people living with HIV (PLHIV) and reduces burden on health facilities. During the COVID‐19 response, PEPFAR worked with ministries of health to scale up MMD and expand eligibility to new groups of PLHIV, including children and pregnant/breastfeeding women. We analysed PEPFAR program data to understand the impact of the policy changes on actual practice. Methods: We conducted a desk review in 21 PEPFAR‐supported countries to identify and collect official documentation released between March and June 2020 addressing changes to MMD guidance during the COVID‐19 response. MMD coverage, the proportion of all ART clients on MMD, was assessed in the calendar quarters preceding the COVID‐19 response (Q4 2019, October–December 2019; and Q1, January–March 2020) and the quarters following the start of the response (Q2 2020, April–June 2020; Q3 2020, July–September, 2020; Q4 2020, October–December 2020). We used the two‐proportion Z‐test to test for differences in MMD coverage pre‐COVID‐19 (Q4 2019) and during implementation of COVID‐19 policy adaptations (Q2 2020). Results and discussion: As of June 2020, 16 of the 21 PEPFAR‐supported countries analysed adapted MMD policy or promoted intensified scale‐up of MMD in response to COVID‐19. MMD coverage for all clients on ART grew from 49% in Q4 2019 pre‐COVID‐19 to 72% in Q2 2020 during COVID‐19; among paediatric clients (< 15), MMD coverage increased from 27% to 51% in the same period. Adaptations to MMD policy were associated with a significantly accelerated growth in the proportion of clients on MMD ( p < 0.001) for all populations, irrespective of age and dispensing interval. Conclusions: Access to MMD markedly expanded during the COVID‐19 pandemic, supporting treatment continuity while mitigating exposure to COVID‐19 at health facilities. This model is beneficial in public health emergencies and during disruptions to the healthcare system. Outside emergency contexts, expanded MMD eligibility extends client‐centred care to previously excluded populations. The success in expanding MMD access during COVID‐19 should motivate countries to recommend broader MMD access as a new standard of care.